<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39056070</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2048-8505</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical kidney journal</Title><ISOAbbreviation>Clin Kidney J</ISOAbbreviation></Journal><ArticleTitle>Effects of ACE inhibitor/ARB therapy and long COVID on kidney disease: a retrospective cohort study using real-world data.</ArticleTitle><Pagination><StartPage>sfae164</StartPage><MedlinePgn>sfae164</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">sfae164</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ckj/sfae164</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The association between angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and severe acute respiratory syndrome coronavirus 2 susceptibility, particularly via ACE-2 receptor upregulation in the kidneys, raises concerns about potential kidney disease risks in long coronavirus disease (COVID) patients. This study explores the association of ACEI/ARB therapy on acute kidney injury (AKI), chronic kidney disease (CKD) and all-cause mortality in patients with and without long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A retrospective cohort study using TriNetX datasets was conducted, with diagnoses of long COVID via <i>International Classification of Diseases, Tenth Revision</i> (ICD-10) codes and prescription for ACEI/ARB as the classification of four cohorts: long COVID ACEI/ARB users (LCAUs), long COVID ACEI/ARB non-users (LCANs), non-long COVID ACEI/ARB users (NLCAUs) and non-long COVID ACEI/ARB non-users (NLCANs). Multivariable stratified Cox proportional hazards regression models assessed the adjusted hazard ratios (aHRs) across groups. Additional analyses were conducted, including time-dependent exposure analysis and comparison with an active comparator, calcium channel blockers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our study included 18&#x2009;168 long COVID and 181&#x2009;680 propensity score-matched non-long COVID patients from October 2021 to October 2023. ACEI/ARB use did not significantly affect the risk of AKI or CKD when comparing LCAUs with LCANs and NLCAUs with NLCANs. However, a protective effect against all-cause mortality was observed {aHR 0.79 [95% confidence interval (CI) 0.65-0.93]} in the NLCAU group compared with the NLCAN group. Conversely, long COVID was associated with increased risks of CKD [aHR 1.49 (95% CI 1.03-2.14)] and all-cause mortality [aHR 1.49 (95% CI 1.00-2.23)] when comparing LCANs with NLCANs. The additional analyses support the primary findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">ACEI/ARB treatment does not increase the incidence of CKD or AKI, regardless of long COVID status. However, long COVID itself is associated with increasing risks of kidney diseases and all-cause mortality.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6875-0025</Identifier><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba</LastName><ForeName>Djibril M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risher</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Duanping</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parent</LastName><ForeName>Leslie J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghahramani</LastName><ForeName>Nasrollah</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0299-9394</Identifier><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chinchilli</LastName><ForeName>Vernon M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Kidney J</MedlineTA><NlmUniqueID>101579321</NlmUniqueID><ISSNLinking>2048-8505</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute kidney injury</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs)</Keyword><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">real-world analysis</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39056070</ArticleId><ArticleId IdType="pmc">PMC11270017</ArticleId><ArticleId IdType="doi">10.1093/ckj/sfae164</ArticleId><ArticleId IdType="pii">sfae164</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford &#xa0;ND. Long COVID and significant activity limitation among adults, by age&#x2014;United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb Mortal Wkly Rep &#xa0;2023;72:866&#x2013;70. 10.15585/mmwr.mm7232a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a3</ArticleId><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff &#xa0;D, Sun &#xa0;A, Ssentongo &#xa0;AE &#xa0;et al. &#xa0;Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open &#xa0;2021;4:e2128568. 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher &#xa0;M, Neugarten &#xa0;J, Bellin &#xa0;E &#xa0;et al. &#xa0;AKI in hospitalized patients with and without COVID-19: a comparison study. J Am Soc Nephrol &#xa0;2020;31:2145&#x2013;57. 10.1681/ASN.2020040509</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020040509</ArticleId><ArticleId IdType="pmc">PMC7461660</ArticleId><ArticleId IdType="pubmed">32669322</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmayer &#xa0;WC, Khairallah &#xa0;P, Charytan &#xa0;DM. Nephrology and COVID-19. JAMA &#xa0;2020;324:1137&#x2013;8. 10.1001/jama.2020.16779</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16779</ArticleId><ArticleId IdType="pubmed">32960255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent &#xa0;J, Aklilu &#xa0;A, Yamamoto &#xa0;Y &#xa0;et al. &#xa0;Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. JAMA Netw Open &#xa0;2021;4:e211095. 10.1001/jamanetworkopen.2021.1095</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.1095</ArticleId><ArticleId IdType="pmc">PMC7948062</ArticleId><ArticleId IdType="pubmed">33688965</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe &#xa0;B, Xie &#xa0;Y, Xu &#xa0;E &#xa0;et al. &#xa0;Kidney outcomes in long COVID. J Am Soc Nephrol &#xa0;2021;32:2851&#x2013;62. 10.1681/ASN.2021060734</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff &#xa0;ER, Madlock-Brown &#xa0;C, Baratta &#xa0;JM &#xa0;et al. &#xa0;Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med &#xa0;2023;21:58. 10.1101/2022.04.18.22273968</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.18.22273968</ArticleId><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson &#xa0;CB, Farzan &#xa0;M, Chen &#xa0;B &#xa0;et al. &#xa0;Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol &#xa0;2022;23:3&#x2013;20. 10.1038/s41580-021-00418-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan &#xa0;S, Chen &#xa0;L, Yang &#xa0;CR &#xa0;et al. &#xa0;Does SARS-CoV-2 infect the kidney? &#xa0;J Am Soc Nephrol &#xa0;2020;31:2746&#x2013;8. 10.1681/ASN.2020081229</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020081229</ArticleId><ArticleId IdType="pmc">PMC7790203</ArticleId><ArticleId IdType="pubmed">33051359</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar &#xa0;S, Liu &#xa0;KD, Go &#xa0;AS &#xa0;et al. &#xa0;Prospective cohort study of renin-angiotensin system blocker usage after hospitalized acute kidney injury. Clin J Am Soc Nephrol &#xa0;2021;16:26&#x2013;36. 10.2215/CJN.10840720</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.10840720</ArticleId><ArticleId IdType="pmc">PMC7792656</ArticleId><ArticleId IdType="pubmed">33272913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidulka &#xa0;P, Fu &#xa0;EL, Leyrat &#xa0;C &#xa0;et al. &#xa0;Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med &#xa0;2020;18:195. 10.1186/s12916-020-01659-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01659-x</ArticleId><ArticleId IdType="pmc">PMC7389346</ArticleId><ArticleId IdType="pubmed">32723383</ArticleId></ArticleIdList></Reference><Reference><Citation>
TriNetX . Publication guidelines. https://trinetx.com/real-world-resources/publications/trinetx-publication-guidelines/ [accessed 1 July 2023].</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention . Clinical overview of long COVID. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html [accessed 2 July 2023].</Citation></Reference><Reference><Citation>
National Library of Medicine . RxNorm overview. https://www.nlm.nih.gov/research/umls/rxnorm/overview.html [accessed 28 October 2023].</Citation><ArticleIdList><ArticleId IdType="pubmed">28792816</ArticleId></ArticleIdList></Reference><Reference><Citation>

Harvey &#xa0;R, Jankus &#xa0;DD, Mosley &#xa0;D. Random assignment of proxy event dates to unexposed individuals in observational studies: an automated technique using SAS&#xae;. https://mwsug.org/proceedings/2012/PH/MWSUG-2012-PH02.pdf [accessed 18 June 2024].</Citation></Reference><Reference><Citation>Schubart &#xa0;JR, Schilling &#xa0;A, Schaefer &#xa0;E &#xa0;et al. &#xa0;Use of prescription opioid and other drugs among a cohort of persons with Ehlers&#x2013;Danlos syndrome: a retrospective study. Am J Med Genet A &#xa0;2019;179:397&#x2013;403. 10.1002/ajmg.a.61031</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.61031</ArticleId><ArticleId IdType="pubmed">30624009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba &#xa0;DM, Risher &#xa0;KA, Ssentongo &#xa0;P &#xa0;et al. &#xa0;Human immunodeficiency virus (HIV) treatment with antiretroviral therapy mitigates the high risk of mental health disorders associated with HIV infection in the US population. Open Forum Infect Dis &#xa0;2023;10:ofad555. 10.1093/ofid/ofad555</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad555</ArticleId><ArticleId IdType="pmc">PMC10686352</ArticleId><ArticleId IdType="pubmed">38033986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;Y, Chinchilli &#xa0;VM, Ssentongo &#xa0;P &#xa0;et al. &#xa0;Association of long COVID with mental health disorders: a retrospective cohort study using real-world data from the USA. BMJ Open &#xa0;2024;14:e079267. 10.1136/bmjopen-2023-079267</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-079267</ArticleId><ArticleId IdType="pmc">PMC10840030</ArticleId><ArticleId IdType="pubmed">38309763</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin &#xa0;PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res &#xa0;2011;46:399&#x2013;424. 10.1080/00273171.2011.568786</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Elm &#xa0;Ev, Altman &#xa0;DG, Egger &#xa0;M &#xa0;et al. &#xa0;Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ &#xa0;2007;335:806&#x2013;8. 10.1136/bmj.39335.541782.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Elixhauser &#xa0;A, Steiner &#xa0;C, Harris &#xa0;DR &#xa0;et al. &#xa0;Comorbidity measures for use with administrative data. Med Care &#xa0;1998;36:8&#x2013;27. 10.1097/00005650-199801000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199801000-00004</ArticleId><ArticleId IdType="pubmed">9431328</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland &#xa0;A, Olafson &#xa0;K, Ramsey &#xa0;CD &#xa0;et al. &#xa0;Epidemiology of critically ill patients in intensive care units: a population-based observational study. Crit Care &#xa0;2013;17:R212. 10.1186/cc13026</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc13026</ArticleId><ArticleId IdType="pmc">PMC4056438</ArticleId><ArticleId IdType="pubmed">24079640</ArticleId></ArticleIdList></Reference><Reference><Citation>House &#xa0;AA, Wanner &#xa0;C, Sarnak &#xa0;MJ &#xa0;et al. &#xa0;Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int &#xa0;2019;95:1304&#x2013;17. 10.1016/j.kint.2019.02.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.02.022</ArticleId><ArticleId IdType="pubmed">31053387</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend &#xa0;RR, Taler &#xa0;SJ. Management of hypertension in chronic kidney disease. Nat Rev Nephrol &#xa0;2015;11:555&#x2013;63. 10.1038/nrneph.2015.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2015.114</ArticleId><ArticleId IdType="pubmed">26215512</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas &#xa0;MC, Brownlee &#xa0;M, Susztak &#xa0;K &#xa0;et al. &#xa0;Diabetic kidney disease. Nat Rev Dis Primer &#xa0;2015;1:15018. 10.1038/nrdp.2015.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.18</ArticleId><ArticleId IdType="pmc">PMC7724636</ArticleId><ArticleId IdType="pubmed">27188921</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe2;mara &#xa0;NOS, Iseki &#xa0;K, Kramer &#xa0;H &#xa0;et al. &#xa0;Kidney disease and obesity: epidemiology, mechanisms and treatment. Nat Rev Nephrol &#xa0;2017;13:181&#x2013;90. 10.1038/nrneph.2016.191</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.191</ArticleId><ArticleId IdType="pubmed">28090083</ArticleId></ArticleIdList></Reference><Reference><Citation>Turakhia &#xa0;MP, Blankestijn &#xa0;PJ, Carrero &#xa0;JJ &#xa0;et al. &#xa0;Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J &#xa0;2018;39:2314&#x2013;25. 10.1093/eurheartj/ehy060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy060</ArticleId><ArticleId IdType="pmc">PMC6012907</ArticleId><ArticleId IdType="pubmed">29522134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen &#xa0;CY, Liao &#xa0;KM. Chronic obstructive pulmonary disease is associated with risk of chronic kidney disease: a nationwide case-cohort study. Sci Rep &#xa0;2016;6:25855. 10.1038/srep25855</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25855</ArticleId><ArticleId IdType="pmc">PMC4863146</ArticleId><ArticleId IdType="pubmed">27166152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisman &#xa0;SH, Hennessey &#xa0;JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med &#xa0;1999;159:79&#x2013;82. 10.1001/archinte.159.1.79</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.159.1.79</ArticleId><ArticleId IdType="pubmed">9892334</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel &#xa0;B. Chronic kidney disease and cancer: a troubling connection. J Nephrol &#xa0;2010;23:253&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823382</ArticleId><ArticleId IdType="pubmed">20349418</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirazian &#xa0;S, Grant &#xa0;CD, Aina &#xa0;O &#xa0;et al. &#xa0;Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep &#xa0;2016;2:94&#x2013;107. 10.1016/j.ekir.2016.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2016.09.005</ArticleId><ArticleId IdType="pmc">PMC5720531</ArticleId><ArticleId IdType="pubmed">29318209</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;Y, Ghahramani &#xa0;N, Razjouyan &#xa0;H &#xa0;et al. &#xa0;The association between proton pump inhibitor use and risk of post-hospitalization acute kidney injury: a multicenter prospective matched cohort study. BMC Nephrol &#xa0;2023;24:150. 10.1186/s12882-023-03211-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-023-03211-4</ArticleId><ArticleId IdType="pmc">PMC10224298</ArticleId><ArticleId IdType="pubmed">37237361</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin &#xa0;PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput &#xa0;2009;38:1228&#x2013;34. 10.1080/03610910902859574</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610910902859574</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine &#xa0;JP, Gray &#xa0;RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc &#xa0;1999;94:496&#x2013;509. 10.1080/01621459.1999.10474144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker &#xa0;LA, Eneanya &#xa0;ND, Coresh &#xa0;J &#xa0;et al. &#xa0;New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med &#xa0;2021;385:1737&#x2013;49. 10.1056/NEJMoa2102953</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102953</ArticleId><ArticleId IdType="pmc">PMC8822996</ArticleId><ArticleId IdType="pubmed">34554658</ArticleId></ArticleIdList></Reference><Reference><Citation>
Agency for Healthcare Research and Quality . LOINC. https://digital.ahrq.gov/loinc [accessed 8 April 2024].</Citation><ArticleIdList><ArticleId IdType="pubmed">21923316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleiss &#xa0;A, Oberbauer &#xa0;R, Heinze &#xa0;G. An unjustified benefit: immortal time bias in the analysis of time-dependent events. Transpl Int &#xa0;2018;31:125&#x2013;30. 10.1111/tri.13081</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.13081</ArticleId><ArticleId IdType="pubmed">29024071</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal &#xa0;P, Moshier &#xa0;E, Ru &#xa0;M &#xa0;et al. &#xa0;Immortal time bias in observational studies of time-to-event outcomes. Cancer Control &#xa0;2018;25:1073274818789355. 10.1177/1073274818789355</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073274818789355</ArticleId><ArticleId IdType="pmc">PMC6053873</ArticleId><ArticleId IdType="pubmed">30021466</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher &#xa0;LD, Lin &#xa0;DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health &#xa0;1999;20:145&#x2013;57. 10.1146/annurev.publhealth.20.1.145</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.publhealth.20.1.145</ArticleId><ArticleId IdType="pubmed">10352854</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund &#xa0;JL, Richardson &#xa0;DB, St&#xfc;rmer &#xa0;T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep &#xa0;2015;2:221&#x2013;8. 10.1007/s40471-015-0053-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-015-0053-5</ArticleId><ArticleId IdType="pmc">PMC4778958</ArticleId><ArticleId IdType="pubmed">26954351</ArticleId></ArticleIdList></Reference><Reference><Citation>

Goyal &#xa0;A, Cusick &#xa0;AS, Thielemier &#xa0;B. ACE inhibitors. Treasure Island, FL: StatPearls Publishing, 2023. https://www.ncbi.nlm.nih.gov/books/NBK430896/. [accessed 7 February 2024].</Citation><ArticleIdList><ArticleId IdType="pubmed">28613646</ArticleId></ArticleIdList></Reference><Reference><Citation>

McKeever &#xa0;RG, Hamilton &#xa0;RJ. Calcium channel blockers. Treasure Island, FL: StatPearls Publishing, 2022. https://www.ncbi.nlm.nih.gov/books/NBK482473/ [accessed 8 December 2023].</Citation><ArticleIdList><ArticleId IdType="pubmed">29494080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostchega &#xa0;Y, Nguyen &#xa0;DT. Hypertension prevalence among adults aged 18 and over: united States, 2017&#x2013;2018. NCHS Data Brief &#xa0;2020;364:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32487290</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar &#xa0;S, Ye &#xa0;F, James &#xa0;MT &#xa0;et al. &#xa0;Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. JAMA Intern Med &#xa0;2018;178:1681&#x2013;90. 10.1001/jamainternmed.2018.4749</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.4749</ArticleId><ArticleId IdType="pmc">PMC6583606</ArticleId><ArticleId IdType="pubmed">30422153</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan &#xa0;M, Vasbinder &#xa0;A, Anderson &#xa0;E &#xa0;et al. &#xa0;Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and outcomes in patients hospitalized for COVID-19. J Am Heart Assoc &#xa0;2021;10:e023535. 10.1161/JAHA.121.023535</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.023535</ArticleId><ArticleId IdType="pmc">PMC9075226</ArticleId><ArticleId IdType="pubmed">34889102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes &#xa0;RD, Macedo &#xa0;AVS, de Barros &#xa0;E &#xa0;et al. &#xa0;Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA &#xa0;2021;325:254&#x2013;64. 10.1001/jama.2020.25864</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.25864</ArticleId><ArticleId IdType="pmc">PMC7816106</ArticleId><ArticleId IdType="pubmed">33464336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;P, Zhu &#xa0;L, Cai &#xa0;J &#xa0;et al. &#xa0;Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res &#xa0;2020;126:1671&#x2013;81. 10.1161/CIRCRESAHA.120.317134</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317134</ArticleId><ArticleId IdType="pmc">PMC7265882</ArticleId><ArticleId IdType="pubmed">32302265</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Society of Cardiology . Position Statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang [accessed 31 October 2023].</Citation></Reference><Reference><Citation>
American College of Cardiology . HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19 [accessed 31 October 2023].</Citation></Reference><Reference><Citation>Wang &#xa0;HE, Muntner &#xa0;P, Chertow &#xa0;GM &#xa0;et al. &#xa0;Acute kidney injury and mortality in hospitalized patients. Am J Nephrol &#xa0;2012;35:349&#x2013;55. 10.1159/000337487</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000337487</ArticleId><ArticleId IdType="pmc">PMC3362180</ArticleId><ArticleId IdType="pubmed">22473149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rewa &#xa0;O, Bagshaw &#xa0;SM. Acute kidney injury&#x2014;epidemiology, outcomes and economics. Nat Rev Nephrol &#xa0;2014;10:193&#x2013;207. 10.1038/nrneph.2013.282</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2013.282</ArticleId><ArticleId IdType="pubmed">24445744</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee &#xa0;PA, Castelli &#xa0;WP, McNamara &#xa0;PM &#xa0;et al. &#xa0;The natural history of congestive heart failure: the Framingham Study. N Engl J Med &#xa0;1971;285:1441&#x2013;6. 10.1056/NEJM197112232852601</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197112232852601</ArticleId><ArticleId IdType="pubmed">5122894</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan &#xa0;CJ. Reducing bias using propensity score matching. J Nucl Cardiol &#xa0;2018;25:404&#x2013;6. 10.1007/s12350-017-1012-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12350-017-1012-y</ArticleId><ArticleId IdType="pubmed">28776312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>